B群脑膜炎球菌疫苗研究进展  

The progress in research of Neisseria meningitidis serogroup B vaccine

作　　者：毕湖冰(综述)[1] 李映波(综述)[1] 姜述德(综述)[1] 

机构地区：[1]中国医学科学院北京协和医学院医学生物学研究所生物制品五室,昆明650118

出　　处：《国际生物制品学杂志》2010年第3期158-161,共4页International Journal of Biologicals

摘　　要：由B群脑膜炎球菌（Neisseria meningitidis serogroup B,MenB）引起的流行性脑脊髓膜炎是全球重要的公共卫生问题之一.由于MenB荚膜多糖与人体组织具有相似性,以及MenB外膜蛋白抗原具有多样性和复杂性,因此目前尚无有效的MenB疫苗.荚膜多糖修饰疫苗可能是一种解决办法 应用反向疫苗学等方法确认MenB的各种保守抗原是重要的疫苗研究途径 将多种无交叉反应的抗原混合制成疫苗同样是未来的研究方向之一.此文就MenB疫苗的研究进展作一综述.Epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroup B （MenB） is one of the most important public health problems throughout the world. Due to similarity between MenB capsu-lar polysaccharide and human tissue,as well as diversity and complexity of MenB outer membrane protein antigen , there is still no effective vaccine. Capsular polysaccharide-modified vaccine is a possible solution. Identification of MenB conserved antigens by novel methods such as reverse vaccinology is an important way for vaccine development. Mixture of many non-cross-reactive antigens is also one of the future directions for vaccine development. The progress in research of MenB vaccine is reviewed in this paper.

关 键 词：奈瑟球菌 脑膜炎 血清B群 疫苗 多糖类 细菌 细菌外膜蛋白质类 

分 类 号：R392-33[医药卫生—免疫学]